vs

Side-by-side financial comparison of Innoviva, Inc. (INVA) and PHOTRONICS INC (PLAB). Click either name above to swap in a different company.

PHOTRONICS INC is the larger business by last-quarter revenue ($210.4M vs $114.6M, roughly 1.8× Innoviva, Inc.). Innoviva, Inc. runs the higher net margin — 143.2% vs 10.9%, a 132.3% gap on every dollar of revenue. On growth, Innoviva, Inc. posted the faster year-over-year revenue change (24.8% vs -5.5%). Over the past eight quarters, Innoviva, Inc.'s revenue compounded faster (21.6% CAGR vs -3.8%).

Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

INVA vs PLAB — Head-to-Head

Bigger by revenue
PLAB
PLAB
1.8× larger
PLAB
$210.4M
$114.6M
INVA
Growing faster (revenue YoY)
INVA
INVA
+30.3% gap
INVA
24.8%
-5.5%
PLAB
Higher net margin
INVA
INVA
132.3% more per $
INVA
143.2%
10.9%
PLAB
Faster 2-yr revenue CAGR
INVA
INVA
Annualised
INVA
21.6%
-3.8%
PLAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
INVA
INVA
PLAB
PLAB
Revenue
$114.6M
$210.4M
Net Profit
$164.2M
$22.9M
Gross Margin
66.0%
33.7%
Operating Margin
34.0%
22.9%
Net Margin
143.2%
10.9%
Revenue YoY
24.8%
-5.5%
Net Profit YoY
707.4%
-32.4%
EPS (diluted)
$2.19
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INVA
INVA
PLAB
PLAB
Q4 25
$114.6M
Q3 25
$107.8M
$210.4M
Q2 25
$100.3M
$211.0M
Q1 25
$88.6M
$212.1M
Q4 24
$91.8M
$222.6M
Q3 24
$89.5M
$211.0M
Q2 24
$99.9M
$217.0M
Q1 24
$77.5M
$216.3M
Net Profit
INVA
INVA
PLAB
PLAB
Q4 25
$164.2M
Q3 25
$89.9M
$22.9M
Q2 25
$63.7M
$8.9M
Q1 25
$-46.6M
$42.9M
Q4 24
$20.3M
$33.9M
Q3 24
$1.2M
$34.4M
Q2 24
$-34.7M
$36.3M
Q1 24
$36.5M
$26.2M
Gross Margin
INVA
INVA
PLAB
PLAB
Q4 25
66.0%
Q3 25
70.1%
33.7%
Q2 25
82.9%
36.9%
Q1 25
82.7%
35.6%
Q4 24
85.1%
37.0%
Q3 24
81.6%
35.6%
Q2 24
85.1%
36.5%
Q1 24
77.5%
36.6%
Operating Margin
INVA
INVA
PLAB
PLAB
Q4 25
34.0%
Q3 25
32.1%
22.9%
Q2 25
48.6%
26.4%
Q1 25
46.7%
24.6%
Q4 24
47.0%
25.1%
Q3 24
48.3%
24.7%
Q2 24
54.7%
25.8%
Q1 24
33.3%
26.6%
Net Margin
INVA
INVA
PLAB
PLAB
Q4 25
143.2%
Q3 25
83.4%
10.9%
Q2 25
63.5%
4.2%
Q1 25
-52.6%
20.2%
Q4 24
22.1%
15.2%
Q3 24
1.4%
16.3%
Q2 24
-34.7%
16.7%
Q1 24
47.1%
12.1%
EPS (diluted)
INVA
INVA
PLAB
PLAB
Q4 25
$2.19
Q3 25
$1.08
$0.39
Q2 25
$0.77
$0.15
Q1 25
$-0.74
$0.68
Q4 24
$0.43
$0.54
Q3 24
$0.02
$0.55
Q2 24
$-0.55
$0.58
Q1 24
$0.46
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INVA
INVA
PLAB
PLAB
Cash + ST InvestmentsLiquidity on hand
$550.9M
$575.8M
Total DebtLower is stronger
$16.0K
Stockholders' EquityBook value
$1.2B
$1.1B
Total Assets
$1.6B
$1.8B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INVA
INVA
PLAB
PLAB
Q4 25
$550.9M
Q3 25
$476.5M
$575.8M
Q2 25
$397.5M
$558.4M
Q1 25
$319.1M
$642.2M
Q4 24
$305.0M
$640.7M
Q3 24
$260.6M
$606.4M
Q2 24
$217.0M
$559.9M
Q1 24
$178.4M
$521.5M
Total Debt
INVA
INVA
PLAB
PLAB
Q4 25
Q3 25
$16.0K
Q2 25
$19.0K
Q1 25
$21.0K
Q4 24
$25.0K
Q3 24
$28.0K
Q2 24
$2.5M
Q1 24
$2.7M
Stockholders' Equity
INVA
INVA
PLAB
PLAB
Q4 25
$1.2B
Q3 25
$1.0B
$1.1B
Q2 25
$714.8M
$1.1B
Q1 25
$646.9M
$1.1B
Q4 24
$691.2M
$1.1B
Q3 24
$668.5M
$1.1B
Q2 24
$665.5M
$1.0B
Q1 24
$703.7M
$1.0B
Total Assets
INVA
INVA
PLAB
PLAB
Q4 25
$1.6B
Q3 25
$1.4B
$1.8B
Q2 25
$1.3B
$1.7B
Q1 25
$1.3B
$1.7B
Q4 24
$1.3B
$1.7B
Q3 24
$1.2B
$1.6B
Q2 24
$1.2B
$1.6B
Q1 24
$1.3B
$1.6B
Debt / Equity
INVA
INVA
PLAB
PLAB
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INVA
INVA
PLAB
PLAB
Operating Cash FlowLast quarter
$54.5M
$50.1M
Free Cash FlowOCF − Capex
$25.2M
FCF MarginFCF / Revenue
12.0%
Capex IntensityCapex / Revenue
11.8%
Cash ConversionOCF / Net Profit
0.33×
2.19×
TTM Free Cash FlowTrailing 4 quarters
$64.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INVA
INVA
PLAB
PLAB
Q4 25
$54.5M
Q3 25
$49.7M
$50.1M
Q2 25
$44.1M
$31.5M
Q1 25
$48.6M
$78.5M
Q4 24
$59.2M
$68.4M
Q3 24
$48.7M
$75.1M
Q2 24
$43.7M
$76.5M
Q1 24
$37.0M
$41.5M
Free Cash Flow
INVA
INVA
PLAB
PLAB
Q4 25
Q3 25
$25.2M
Q2 25
$-29.1M
Q1 25
$43.3M
Q4 24
$25.2M
Q3 24
$48.4M
$50.7M
Q2 24
$56.5M
Q1 24
$-1.8M
FCF Margin
INVA
INVA
PLAB
PLAB
Q4 25
Q3 25
12.0%
Q2 25
-13.8%
Q1 25
20.4%
Q4 24
11.3%
Q3 24
54.1%
24.0%
Q2 24
26.0%
Q1 24
-0.8%
Capex Intensity
INVA
INVA
PLAB
PLAB
Q4 25
Q3 25
11.8%
Q2 25
28.7%
Q1 25
16.6%
Q4 24
0.0%
19.4%
Q3 24
0.3%
11.6%
Q2 24
0.0%
9.2%
Q1 24
0.0%
20.0%
Cash Conversion
INVA
INVA
PLAB
PLAB
Q4 25
0.33×
Q3 25
0.55×
2.19×
Q2 25
0.69×
3.55×
Q1 25
1.83×
Q4 24
2.91×
2.02×
Q3 24
40.14×
2.18×
Q2 24
2.11×
Q1 24
1.01×
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INVA
INVA

Royalty$54.9M48%
Xacduro$32.1M28%
Giapreza$19.6M17%
Xerava$7.3M6%

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

Related Comparisons